The Institute of Cancer Research shared a post on LinkedIn:
“The GRAIL Galleri multi‑cancer blood test has failed to achieve its key objective in a major NHS trial.
Detecting cancer early is key to saving lives.
We welcome innovations that could one day transform early detection of cancer for millions of people around the world.
ICR’s Professor Richard Houlston told BBC News, it is essential that bold claims are backed by transparent, comprehensive evidence.
He says: “Without mortality data and a transparent account of harms, including false positives, unnecessary procedures, and opportunity cost, claims of population benefit from multi‑cancer early detection remain speculative.”
Multi‑cancer early detection is an exciting field, but these latest findings underscore why rigorous trials, clear reporting, and proven patient benefit must guide decisions about future NHS screening.
We look forward to seeing the full data at American Society of Clinical Oncology (ASCO) later this year.
Read more from the BBC here”
Other OncoDaily articles about The Institute of Cancer Research.